Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis (NASH)

Global Non-alcoholic Steatohepatitis (NASH) Market to Reach US$181.5 Billion by 2030

The global market for Non-alcoholic Steatohepatitis (NASH) estimated at US$8.3 Billion in the year 2023, is expected to reach US$181.5 Billion by 2030, growing at a CAGR of 55.3% over the analysis period 2023-2030. Vitamin E & Pioglitazone Drug Type, one of the segments analyzed in the report, is expected to record a 45.5% CAGR and reach US$59.7 Billion by the end of the analysis period. Growth in the Obeticholic Acid (OCA) Drug Type segment is estimated at 43.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.5 Billion While China is Forecast to Grow at 51.8% CAGR

The Non-alcoholic Steatohepatitis (NASH) market in the U.S. is estimated at US$2.5 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$24.0 Billion by the year 2030 trailing a CAGR of 51.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 47.4% and 46.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 35.9% CAGR.

Global Non-alcoholic Steatohepatitis (NASH) Market - Key Trends and Drivers Summarized

Why Is Non-Alcoholic Steatohepatitis (NASH) a Rising Global Health Crisis?

Non-alcoholic steatohepatitis (NASH) has rapidly emerged as a significant global health issue, driven largely by the rising incidence of obesity and type 2 diabetes worldwide. NASH is a more severe form of non-alcoholic fatty liver disease (NAFLD) and is characterized by liver inflammation and fibrosis, which can lead to cirrhosis, liver failure, and even liver cancer. Unlike other liver diseases, NASH is not associated with alcohol consumption but rather with metabolic risk factors such as insulin resistance and hyperlipidemia. The disease is often asymptomatic until it progresses to advanced stages, making early detection and intervention critical yet challenging. With millions of people at risk globally, NASH is poised to become the leading cause of liver transplants in the coming decades, particularly in regions where obesity and diabetes are most prevalent. The silent and progressive nature of NASH underscores the urgent need for increased awareness, better diagnostic tools, and effective treatments.

How Are Innovations in Diagnostics and Treatment Shaping the Future of NASH Management?

The management of NASH is undergoing a significant transformation, thanks to innovations in both diagnostics and treatment. Historically, diagnosing NASH has been difficult, often requiring invasive liver biopsies to confirm the presence of inflammation and fibrosis. However, the advent of non-invasive diagnostic technologies, such as elastography and advanced biomarker assays, is revolutionizing the way NASH is detected and monitored. These tools not only reduce the need for biopsies but also enable earlier and more accurate diagnosis, which is critical for timely intervention. On the treatment front, there is a burgeoning pipeline of drugs in development, targeting various pathways involved in NASH progression, including fibrosis, oxidative stress, and lipid metabolism. Some of these therapies have shown promising results in clinical trials, bringing hope that effective treatments may soon be available. These advancements are expected to greatly improve patient outcomes by halting or even reversing disease progression, thus reducing the burden of NASH on healthcare systems worldwide.

What Challenges Does the NASH Market Face and What Opportunities Lie Ahead?

While the NASH market holds immense potential, it is not without its challenges. One of the most significant hurdles is the high cost and complexity of developing effective NASH therapies. Given the heterogeneity of the disease, with its varying stages and underlying causes, finding a one-size-fits-all treatment has proven difficult. Moreover, the lack of approved therapies has led to an unmet need in the market, where patients have limited options beyond lifestyle modifications. Despite these challenges, there are several opportunities on the horizon. The growing understanding of the molecular mechanisms underlying NASH is paving the way for the development of targeted therapies that could offer more personalized and effective treatment options. Additionally, the increasing focus on early diagnosis and intervention is expanding the market for diagnostic tools and creating demand for therapies that can address the disease in its early stages. As awareness of NASH continues to rise, particularly among healthcare providers and at-risk populations, there is a growing market opportunity for both pharmaceutical and diagnostic companies.

What Factors Are Driving Growth in the NASH Market?

The growth in the NASH market is driven by several factors that reflect advancements in technology, shifts in patient demographics, and evolving healthcare practices. One of the primary drivers is the escalating prevalence of obesity and type 2 diabetes, which are strongly linked to the development of NASH. This expanding patient population is creating a significant demand for both diagnostic tools and therapeutic options. Additionally, innovations in non-invasive diagnostics are enabling earlier detection of NASH, which in turn increases the number of patients eligible for treatment and intervention. The robust pipeline of drugs under development, targeting various mechanisms of the disease, is another crucial factor driving market growth, with several candidates expected to receive approval and enter the market soon. Moreover, the trend towards personalized medicine is gaining traction in the NASH space, with therapies being developed to cater to specific patient subgroups, thereby improving efficacy and reducing adverse effects. The increasing awareness of NASH among healthcare professionals and patients is also contributing to market expansion, as early detection and treatment become more prioritized in clinical settings. Collectively, these factors are fueling the rapid growth of the NASH market, making it one of the most dynamic areas in the field of liver disease treatment.

Select Competitors (Total 12 Featured) -

• 89bio
• Akero Therapeutics
• Arrowhead Pharmaceuticals, Inc.
• Belite Bio Inc.
• Boehringer Ingelheim International GmbH
• Caldan Therapeutics Ltd
• Elixir Rx Solutions, LLC
• Gilead Sciences, Inc.
• Immuron Ltd.
• Intercept Pharmaceuticals, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.